Læknablaðið - 01.11.2014, Blaðsíða 34

602 LÆKNAblaðið 2014/100
S a G a l æ k n i S F R æ ð i n n a R
Vísindin efla alla dáð,
orkuna styrkja, viljann hvessa,
vonina glæða, hugann hressa,
farsældum vefja lýð og láð.
Skyldur okkar sem vísindamanna eru margþættar. Hefð­
bundna háskólahlutverkið er að afla nýrrar þekkingar og miðla
henni til nemenda og almennings. Nýsköpunarhlutverkið, það er
að nýta vísindalega þekkingu til atvinnu­ og verðmætasköpunar,
er tiltölulega nýtilkomið hér á Íslandi.
Síðasta ljóðlína Jónasar: „farsældum vefja lýð og láð“ vísar
kannski til þessa hlutverks vísindanna. Vísindaleg nýsköpun er
ein meginundirstaða hagsældar nútímaþjóðfélaga. Bandaríska
viðskiptaráðuneytið áætlar að tækniþróun og nýsköpun standi
undir 75% af vexti þjóðarbúsins frá stríðslokum. Hlutverk Háskóla
Íslands og okkar sem vísindamanna er meðal annars að finna og
skapa tækifæri til nýsköpunar í atvinnulífi og verðmætasköpunar
fyrir okkur öll. Framtíð íslensks þjóðarbús á nokkuð undir því að
okkur takist vel til.
1. Machemer R. [Development of pars plana vitrectomy. My
personal contribution]. Klin Monbl Augenheilkd 1995;
207: 147­61. Review. German.
2. Stefánsson E, Machemer R, de Juan E Jr, McCuen BW 2nd,
Peterson J. Retinal oxygenation and laser treatment in
patients with diabetic retinopathy. Am J Ophthalmol 1992;
113: 36­8.
3. Stefánsson E, Wilson CA, Schoen T, Kuwabara T.
Experimental ischemia induces cell mitosis in the adult rat
retina. Invest Ophthalmol Vis Sci 1988; 29:1050­5.
4. Kristinsson JK, Fridriksdóttir H, Thórisdóttir S, Sigurd­
ardóttir AM, Stefánsson E, Loftsson T. Dexamethasone­
cyclodextrin­polymer co­complexes in aqueous eye drops.
Aqueous humor pharmacokinetics in humans. Invest
Ophthalmol Vis Sci 1996; 37:1 199­203.
5. Tanito M, Hara K, Takai Y, Matsuoka Y, Nishimura N,
Jansook P, et al. Topical dexamethasone­cyclodextrin
microparticle eye drops for diabetic macular edema.
Invest Ophthalmol Vis Sci 2011; 52: 7944­8
6. Jóhannesson G, Moya­Ortega MD, Asgrímsdóttir GM,
Lund SH, Thorsteinsdóttir M, Loftsson T, et al. Kinetics
of γ-cyclodextrin nanoparticle suspension eye drops in
tear fluid.Acta Ophthalmol 2013. doi: 10.1111/aos.12334.
[Epub ahead of print]
7. Jóhannesson G, Kurkov SV, Jansook P, Loftsson T,
Stefánsson E, Gudmundsdottir BS, et al. ­Cyclodextrin
nanoparticle eye drops with dorzolamide: effect on
intraocular pressure in man. J Ocul Pharmacol Ther 2014;
30: 35­41.
8. Jansook P, Muankaew C, Stefánsson E, Loftsson T.
Development of eye drops containing antihypertensive
drugs: formulation of aqueous irbesartan/γCD eye drops.
Pharm Dev Technol 2014. [Epub ahead of print]
9. Stefansson E, Landers MB 3rd, Wolbarsht ML.
Oxygenation and vasodilatation in relation to diabetic
and other proliferative retinopathies. Ophthalmic Surg
1983;14: 209­26.
10. Stefánsson E. Ocular oxygenation and the treatment of
diabetic retinopathy. Surv Ophthalmol 2006; 51: 364­80.
11. Einstein A. On the Movement of Small Particles
Suspended in Stationary Liquids Required by the
Molecular­Kinetic Theory of Heat. Ann der Physik 1905;
17: 549­60.
12. Gisladottir S, Loftsson T, Stefansson E. Diffusion
characteristics of vitreous humour and saline solution
follow the Stokes Einstein equation. Graefes Arch Clin Exp
Ophthalmol 2009; 247: 1677­84.
13. Stefánsson E, Geirsdóttir A, Sigurdsson H. Metabolic
physiology in age related macular degeneration. Prog
Retin Eye Res 2011; 30: 72­80.
14. Stefánsson E. Physiology of vitreous surgery. Graefes Arch
Clin Exp Ophthalmol 2009; 247: 147­63.
15. Stefánsson E. Physiology of vitreous surgery. Graefes Arch
Clin Exp Ophthalmol 2009; 247: 147­63.
16. Stefánsson E, Jensen PK, Eysteinsson T, Bang K, Kiilgaard
JF, Dollerup J, et al. Optic nerve oxygen tension in pigs
and the effect of carbonic anhydrase inhibitors. Invest
Ophthalmol Vis Sci 1999; 40: 2756­61.
17. Stefánsson E, Pedersen DB, Jensen PK, la Cour M,
Kiilgaard JF, Bang K, et al. Optic nerve oxygenation. Prog
Retin Eye Res 2005; 24: 307­32.
18. Pedersen DB, Stefánsson E, Kiilgaard JF, Jensen PK,
Eysteinsson T, Bang K, et al. Optic nerve pH and PO2: the
effects of carbonic anhydrase inhibition, and metabolic
and respiratory acidosis. Acta Ophthalmol Scand 2006; 84:
475­80.
19. Noergaard MH, Bach­Holm D, Scherfig E, Bang K, Jensen
PK, Kiilgaard JF, et al. Dorzolamide increases retinal
oxygen tension after branch retinal vein occlusion. Invest
Ophthalmol Vis Sci 2008; 49: 1136­41. doi: 10.1167/iovs.07­
0508.
20. Hardarson SH, Harris A, Karlsson RA, Halldorsson
GH, Kagemann L, Rechtman E, et al. Automatic retinal
oximetry. Invest Ophthalmol Vis Sci 2006; 47: 5011­6.
21. Hardarson SH. Retinal oximetry. Acta Ophthalmol 2013;
91 Thesis 2:1­47. doi: 10.1111/aos.12086.
22. Hardarson SH. Retinal oximetry. Acta Ophthalmol 2013;
91: 489­90. doi: 10.1111/aos.12239.
23. Traustason S, Kiilgaard JF, Karlsson RA, Hardarson SH,
Stefansson E, la Cour M. Spectrophotometric retinal
oximetry in pigs. Invest Ophthalmol Vis Sci 2013; 54: 2746­
51. doi: 10.1167/iovs.12­11284.
24. Geirsdottir A, Hardarson SH, Olafsdottir OB, Stefánsson
E Retinal oxygen metabolism in exudative age­related
macular degeneration. Acta Ophthalmol 2014; 92: 27­33.
25. Olafsdottir OB, Vandewalle E, Abegão Pinto L, Geirsdottir
A, De Clerck E, Stalmans P, et al. Retinal oxygen
metabolism in healthy subjects and glaucoma patients.
Br J Ophthalmol 2014; 98: 329­33. doi: 10.1136/bjop­
hthalmol­2013­303162.
26. Kristjansdottir JV, Hardarson SH, Harvey AR, Olafsdottir
OB, Eliasdottir TS, Stefánsson E. Choroidal oximetry
with a noninvasive spectrophotometric oximeter. Invest
Ophthalmol Vis Sci 2013; 54: 3234­9. doi: 10.1167/iovs.12­
10507.
27. Vandewalle E, Abegão Pinto L, Olafsdottir OB, Stalmans
I. Phenylephrine 5% added to tropicamide 0.5% eye
drops does not influence retinal oxygen saturation values
or retinal vessel diameter in glaucoma patients. Acta
Ophthalmol 2013; 91: 733­7.
28. Danielsen R, Jónasson F, Helgason T. Prevalence of
retinopathy and proteinuria in type 1 diabetics in Iceland.
Acta Med Scand 1982; 212: 277­80.
29. Kristinsson JK, Hauksdóttir H, Stefánsson E, Jónasson F,
Gíslason I. Active prevention in diabetic eye disease. A
4­year follow­up. Acta Ophthalmol Scand 1997; 75: 249­54.
30. Kristinsson JK, Stefánsson E, Jónasson F, Gíslason I,
Björnsson S. Screening for eye disease in type 2 diabetes
mellitus. Acta Ophthalmol (Copenh) 1994; 72: 341­6.
31. Kristinsson JK, Stefánsson E, Jónasson F, Gíslason I,
Björnsson S. Systematic screening for diabetic eye disease
in insulin dependent diabetes. Acta Ophthalmol (Copenh)
1994; 72: 72­8.
32. Olafsdottir E, Andersson DK, Dedorsson I, Stefánsson
E. The prevalence of retinopathy in subjects with and
without type 2 diabetes mellitus. Acta Ophthalmol 2014;
92: 133­7. doi: 10.1111/aos.12095.
33. Olafsdottir E, Andersson DK, Stefánsson E. The preva­
lence of cataract in a population with and without type 2
diabetes mellitus. Acta Ophthalmol 2012; 90: 334­40.
34. Kristinsson JK, Gudmundsson JR, Stefánsson E, Jónasson
F, Gíslason I, Thórsson AV. Screening for diabetic retino­
pathy. Initiation and frequency. Acta Ophthalmol Scand
1995; 73: 525­8.
35. Olafsdóttir E, Stefánsson E. Biennial eye screening in
patients with diabetes without retinopathy: 10­year
experience. Br J Ophthalmol 2007; 91: 1599­601.
36. Stefánsson E. Man versus machine: is technology a bless­
ing or a barrier in screening for diabetic eye disease? Acta
Ophthalmol Scand 2004; 82: 643­4.
37. Stefánsson E, Bek T, Porta M, Larsen N, Kristinsson JK,
Agardh E. Screening and prevention of diabetic blindness.
Acta Ophthalmol Scand 2000; 78: 374­85.
38. Aspelund T, Thornórisdóttir O, Olafsdottir E, Gud­
mundsdottir A, Einarsdóttir AB, Mehlsen J, et al.
Individual risk assessment and information technology
to optimise screening frequency for diabetic retinopathy.
Diabetologia 2011; 54: 2525­32. doi: 10.1007/s00125­011­
2257­7.
Heimildir
&
Victoza (líraglútíð)
leiðir til allt að:1
1,5%
lækkunar á HbA1c
frá 8,4 % HbA1c til 6,9 % HbA1c
3,7 kg
þyngdartaps
Magi
Victoza seinkar
magatæmingu og
veitir því aukna
mettunartilnningu. 2,3
Briskirtill
Victoza virkjar
betafrumurnar sem
losa insúlín þegar
blóðsykur er hár. 2,3
Lifur
Victoza hamlar
seytingu glúkagons
og dregur úr útskilnaði
glúkósa frá lifur. 2,3
Matarlyst
Victoza dregur úr
matarlyst, sem leiðir til
minnkaðrar fæðuneyslu. 2
líraglútíð
Staða sérfræðilæknis
og deildarlæknis
SÁÁ auglýsir lausar til umsóknar stöður sérfræðilæknis og deildarlæknis á Sjúkrahúsinu
Vogi. Nánari upplýsingar veitir Þórarinn Tyrfingsson í síma 824 7600, thorarinn@saa.is